Large, real-world studies demonstrate continued excellent outcomes for patients receiving edwards sapien tavr

Washington--(business wire)--edwards lifesciences (nyse: ew) announced today at cardiovascular research technologies (crt) 2024 the compelling results from two large, real-world studies based on tvt registry data that demonstrated continued excellent outcomes for patients treated with the edwards sapien valve platform. a study of edwards' latest tavr technology, the sapien 3 ultra resilia valve, found lower rates of paravalvular leak (pvl) at 30 days, lower echo-derived gradients and larger eff.
EW Ratings Summary
EW Quant Ranking